Lumicks

Lumicks is a company based in the Netherlands that develops and sells innovative instruments for dynamic single-molecule and cell avidity analysis. The company was founded in 2014 as a spin-off from the Vrije Universiteit Amsterdam, where the core technology was developed by a team of physicists and biologists. LUMICKS has its headquarters in Amsterdam, where it also has its research and development, manufacturing, and sales departments. Lumicks also has offices in the United States, China, and India, and distributors in several other countries. Lumicks reported revenue of $43.7M for FY 2022.

Lumicks aims to advance science and improve human health by providing tools that unlock the measurement of forces and interactions in biology. Its instruments allow researchers to build the bridge between structure and function at both a molecular and a cellular level, by applying and measuring forces around biological interactions. This enables the detailed real-time analysis of underlying biological mechanisms, such as DNA repair, protein folding, cytoskeletal transport, phase separation, and immunotherapy.

Lumicks has received several awards and recognitions for its innovative technology and business achievements. In 2018, LUMICKS was named the National Icon of the Netherlands by the Ministry of Economic Affairs and Climate Policy. In 2019, LUMICKS won the Academic Enterprise Award (ACES) for Best Life Sciences Spin-out. In 2020, Lumicks raised €93 million in a Series D funding round led by Gilde Healthcare. In 2021, Lumicks became a public company listed on Euronext Amsterdam with a market capitalization of over €1 billion.

Foundation: 2014

Headquarters: Amsterdam, Netherlands.

Website: https://lumicks.com/